NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free CMRX Stock Alerts $0.99 +0.02 (+2.07%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.95▼$1.0050-Day Range$0.88▼$1.2452-Week Range$0.88▼$1.57Volume90,957 shsAverage Volume232,175 shsMarket Capitalization$88.51 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Chimerix alerts: Email Address Chimerix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside710.1% Upside$8.00 Price TargetShort InterestHealthy1.71% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment0.62Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector167th out of 921 stocksPharmaceutical Preparations Industry68th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has only been the subject of 1 research reports in the past 90 days.Read more about Chimerix's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.71% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently increased by 3.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 3.1 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chimerix this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows3 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of Chimerix is held by insiders.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chimerix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.85) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chimerix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIweirdest stock market marches onFor the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market”Graham is hosting a “tell all” workshop about his Apex Indicator here About Chimerix Stock (NASDAQ:CMRX)Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More CMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Stock News HeadlinesMay 15 at 4:36 AM | americanbankingnews.comChimerix (NASDAQ:CMRX) Lifted to Hold at StockNews.comMay 14, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Stock Crosses Below 200 Day Moving Average of $1.00May 3, 2024 | markets.businessinsider.comBuy Rating Justified by Chimerix’s Upcoming Catalysts and Strong FinancialsMay 2, 2024 | markets.businessinsider.comStrong Buy Rating for Chimerix on Robust Financials and Promising Drug PipelineMay 2, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comChimerix’s Strong Financials and Promising ONC201 Developments Merit Buy RatingMay 2, 2024 | finance.yahoo.comChimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 2, 2024 | au.finance.yahoo.comQ1 2024 Chimerix Inc Earnings CallMay 1, 2024 | msn.comChimerix GAAP EPS of -$0.25May 1, 2024 | sfgate.comChimerix: Q1 Earnings SnapshotMay 1, 2024 | globenewswire.comChimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateApril 30, 2024 | markets.businessinsider.comWhat Wall Street expects from Chimerix's earningsApril 24, 2024 | globenewswire.comChimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024April 16, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 15, 2024 | finance.yahoo.comWe Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth CarefullyMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 2.000 callMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 1.000 putMarch 5, 2024 | finance.yahoo.comChimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 2, 2024 | seekingalpha.comChimerix, Inc. (CMRX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comChimerix: Tackling A Strong Unmet Need With Promising DataMarch 1, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Chimerix Amid Progress in Dordaviprone’s Phase III Study and Strong Financial OutlookFebruary 29, 2024 | finanznachrichten.deChimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateFebruary 29, 2024 | finance.yahoo.comChimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comChimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateSee More Headlines Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees72Year Founded2000Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+710.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net Margins-25,337.96% Pretax Margin-201,443.91% Return on Equity-41.32% Return on Assets-37.83% Debt Debt-to-Equity RatioN/A Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$320,000.00 Price / Sales276.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.51Miscellaneous Outstanding Shares89,630,000Free Float80,667,000Market Cap$88.51 million OptionableOptionable Beta1.13 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael T. Andriole M.B.A. (Age 51)CEO, President & Director Comp: $820kDr. Roy W. Ware MBAPh.D., Chief Manufacturing Technology OfficerKey CompetitorsVaccitechNASDAQ:VACCBarinthus BiotherapeuticsNASDAQ:BRNSLifeVantageNASDAQ:LFVNOncolytics BiotechNASDAQ:ONCYMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCBought 291,981 shares on 5/10/2024Ownership: 2.426%Koshinski Asset Management Inc.Bought 40,000 shares on 5/9/2024Ownership: 0.045%Marquette Asset Management LLCBought 22,709 shares on 5/7/2024Ownership: 0.129%Assenagon Asset Management S.A.Sold 44,923 shares on 4/24/2024Ownership: 0.509%Michael T AndrioleSold 1,744 sharesTotal: $1,813.76 ($1.04/share)View All Insider TransactionsView All Institutional Transactions CMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price target for 2024? 3 brokerages have issued 1 year target prices for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 710.1% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2024? Chimerix's stock was trading at $0.9625 at the beginning of the year. Since then, CMRX stock has increased by 2.6% and is now trading at $0.9875. View the best growth stocks for 2024 here. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CMRX earnings forecast. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.04. Chimerix had a negative trailing twelve-month return on equity of 41.32% and a negative net margin of 25,337.96%. During the same quarter last year, the company posted ($0.24) earnings per share. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). Who are Chimerix's major shareholders? Chimerix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.43%), Assenagon Asset Management S.A. (0.51%), Marquette Asset Management LLC (0.13%), Koshinski Asset Management Inc. (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMRX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
